BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal

BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.

Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.

The letter, signed by approximately 85 patient groups, requests appropriation for CAN in FY2011

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Frequently Asked Questions Document

Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.

BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability and suitability of a clinical trial.

BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.